Acute Gout Flare Market

Key Highlights

• Acute gout flare, influenced by age, gender, and lifestyle, poses a significant burden globally, impacting patients' quality of life and increasing healthcare costs. Despite its rising cases, underdiagnosis and undertreatment are common, emphasizing the need for improved awareness and management strategies to address disparities and reduce the overall burden on individuals and healthcare systems. 
• Gender-specific cases of acute gout flare often show a higher number of cases among males, particularly in middle-aged to older populations. This discrepancy is largely attributed to hormonal differences, with males typically experiencing higher serum uric acid levels compared to females due to the influence of testosterone. However, females can also be affected, particularly after menopause due to declining estrogen levels.
• The gout market is anticipated to experience a favorable expansion, fueled by the introduction of emerging therapies and the growing requirement for efficient management of the condition. Some of the key players are Olatec Therapeutics, Dyve Biosciences, among others.
• The acute gout flare market is predicted to undergo significant growth due to a strong pipeline of innovative drug candidates worldwide. Emerging therapies such as Interleukin (IL)-1 Inhibitors (Dapansutrile) and DYV700 are aimed at addressing the unmet needs within the market.

DelveInsight’s comprehensive report titled “Acute Gout Flare — Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of Acute Gout Flare. The report presents historical and projected epidemiological data covering Incident Cases of Acute Gout Flare, Age-specific Incident Cases of Acute Gout Flare, and Gender-specific Incident Cases of Acute Gout Flare. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in Acute Gout Flare. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Acute Gout Flare Overview

A gout is a form of inflammatory arthritis that is triggered by the crystallization of monosodium urate (MSU) inside the joints and is preceded by hyperuricemia. Gout progresses in 4 stages: Asymptomatic hyperuricemia, Acute gout flare/attack, inter-critical period, and if left untreated the disease reaches Chronic tophaceous gout. In general, Gout is a manageable disease if diagnosed and treated properly.

Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, and decreased physical function as the patients experience symptoms such as severe pain and inflammation in one or more joints. Epidemiology studies show that Gout has become more prevalent over the past few decades, affecting over 3% of adults in the US. 

Risk factors include genetics, age, gender, and diet. These factors may contribute to a high serum uric acid level, currently defined as a value of at least 6.8 mg per dL (405 μmol per L). Hyperuricemia is a primary risk factor for gout. Gout is more prevalent in males than females; it affects adults more than 60 years of age than the younger population; Genetic predisposition for Gout plays a vital role in disease progression. Excessive consumption of foods such as red meat, seafood, sugar-sweetened soft drinks, fructose, and alcohol increases the risk of developing hyperuricemia. 

Acute Gout Flare Diagnosis and Treatment Algorithm 

Acute gout flare is characterized by a sudden onset of joint pain, swelling, redness, and tenderness, often peaking within 24 hours. The first metatarsophalangeal joint is commonly affected. Clinical signs, such as the presence of tophi and elevated serum uric acid levels, can aid in the diagnosis. Identifying monosodium urate crystals in the joint fluid is crucial for confirming the diagnosis. Imaging techniques, like ultrasound and dual-energy CT, can also support the diagnosis. Considering differential diagnoses, such as septic arthritis, is essential. Prompt and accurate diagnosis is key for the effective management of acute gout flares.

Treatment of acute gout attacks involves pharmacological therapy with Non-Steroidal anti-inflammatory drugs (NSAIDs) or COX-2 Inhibitors, Anti-inflammatory Corticosteroids, Colchicine, or local steroid injections. Immediate therapy for acute gout attacks aims to reduce pain and promote a full, early resolution. In patients with frequent flare and contraindications to conventional treatments, an Interleukin-1 blocker should be considered. With scientific improvements and a better understanding of disease pathogenesis, promising treatment paradigms like inflammatory inhibitors are evolving.

Acute Gout Flare Epidemiology

The epidemiology section on the Acute Gout Flare market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence/incidence of Acute Gout Flare. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• According to the analysis, the annual incidence of gout is 2.68 per 1000 persons in the UK.
• By gender, men are more predisposed to gout than females. In Western countries, it occurs in 3–6% of men and 1–2% of women. In some countries, prevalence may increase up to 10%. 
• Recent reports of the prevalence and incidence of gout vary widely according to the population studied and methods employed but range from a prevalence of <1% to 6.8% and an incidence of 0.58-2.89 per 1,000 person-years. Gout is more prevalent in men than in women, with increasing age. Both prevalence and incidence of gout seem to be rising across the globe.
• Gout affects approximately 9.2 million people in the US (about 3.9% of the adult population). It is more common in men and older people.
• According to the analysis, the standardized prevalence of gout in Germany was 1.63%, equating to approximately 1.325 million affected patients. The standardized incidence rate was 0.45%. The male-to-female ratio stood at 3.2 for prevalence and 2.7 for incidence. The mean age of diagnosis is estimated to be 66 years.
• The incidence and prevalence of gout increases with age. The incidence of gout per 100,000 by age was as follows: 18–29 yrs, 31; 30–39 yrs, 69; 40–49 yrs, 67; 50–59 yrs, 155; 60–69 yrs, 244; 70–79, 294; and ≥80, 367.

Acute Gout Flare Market Outlook

Acute Gout attack treatment includes first-line treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or COX-2 Inhibitors, Anti-inflammatory Corticosteroids, Colchicine, or local steroid injections. Immediate therapy for acute gout attacks aims to reduce pain and promote a full, early resolution. In most cases, acute attacks are followed by recurrent attacks with decreasing inter-critical periods, leading to Chronic Gout. Chronic gout manifests by chronic synovitis, bony erosions, cartilage damage, and tophi formation.

Considering IL-1 blockers are recommended by the EULAR for managing gout flares in patients with frequent episodes who cannot use NSAIDs, colchicine, or steroids (oral or injectable). Canakinumab, a durable IL-1 beta antibody, is approved by the European Medical Agency after two RCT trials versus intramuscular triamcinolone actinide. Moreover, Anakinra, an IL-1 receptor antagonist, is employed off-label in such instances. Urate Lowering Drugs (ULDs) are prescribed to regulate blood uric acid levels.

Recently, in August 2023, the FDA expanded the approval of ILARIS (canakinumab) to include the treatment of gout flares in adults. This approval is for patients unable to take NSAIDs or colchicine, or who do not respond adequately to these treatments, and for whom repeated corticosteroid courses are not suitable.

With recent Research & Development in various marketed IL-1 Blockers, for the treatment and management of Gout flares, the Acute Gout Flare Market is poised to experience huge changes during the study period, as they also have an established safety and side-effect profile. 

According to DelveInsight, the Acute Gout Flare market in the 7MM is expected to change significantly during the forecast period 2024–2034.

Acute Gout Flare Drug Chapters 

Marketed Acute Gout Flare Drugs

ILARIS (canakinumab): NOVARTIS PHARMS

ILARIS, or interleukin-1 receptor antagonists, offer a promising approach for managing acute gout flares. By inhibiting the action of interleukin-1, a key inflammatory mediator in gout, ILARIS help reduce pain and inflammation associated with acute attacks. This medication provide an effective alternative for patients who may not respond adequately to traditional therapies such as nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine. Additionally, ILARIS have shown potential in preventing recurrent gout flares, offering a comprehensive treatment option for individuals with gout.

Note: Detailed marketed therapies assessment and complete list will be provided in the final report.

Emerging Acute Gout Flare Drugs

The market has a promising outlook with many emerging therapies. Companies all over the globe are persistently working towards the development of new treatment therapies. Some of the therapies in the developmental pipeline includes Dapansutrile by Olatec Therapeutics, DYV700 by Dyve Biosciences, and others.

OLT1177 (Dapansutrile): Olatec Therapeutics

It is an investigational small molecule, a new chemical entity that specifically binds to and blocks NLRP3 (nucleotide-binding and oligomerization domain [NOD]-, leucine-rich repeat-, pyrin domain-containing 3), the sensor molecule integral in the formation of the NLRP3 inflammasome. It is currently recruiting for in Phase II/III clinical trial and has been well tolerated and shown to improve clinical outcomes in patients with acute gout flare. The company has announced positive results in Phase IIa (Study OLT1177-05). This molecule represents the first known selective NLRP3 inhibitor to demonstrate clinical benefit, safety, and a reduction in systemic inflammation.

DYV700: Dyve Biosciences

DYV700, Dyve's groundbreaking therapeutic derived from their proprietary skin penetration platform technology. In 2022, Dyve achieved a major milestone with the successful completion of a Phase II study, demonstrating the efficacy of their proprietary DYV700 in reducing pain associated with the acidic microenvironment of acute gouty arthritis. This breakthrough was reinforced by biomarker data, affirming the effectiveness of transdermal pH modulation in addressing the acidic disease microenvironment. Moreover, the potential of DYV-700 offers hope to millions of gout patients grappling with the intense pain of acute gout flares. Given the limited innovation in acute gout treatment and the slow onset and adverse effects of current options, DYV-700's promising pilot study results suggest a transformative shift in acute gout management may be on the horizon.

Drugs that are approved for the indication of “Rheumatoid Arthritis” are also being studied for Acute Gout Flares, which makes the inclusion of these in our pipeline study.

Note: Detailed emerging therapies assessment and complete list will be provided in the final report.

Acute Gout Flare Market Segmentation

DelveInsight’s ‘Acute Gout Flare Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future Acute Gout Flare market, segmented within countries and by therapies. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies. 

Acute Gout Flare Market Size by Countries

The Acute Gout Flare market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2023, the United States held a significant share of the overall 7MM (Seven Major Markets) Acute Gout Flare market, primarily attributed to the country's higher prevalence/incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Acute Gout Flare Market Size by Therapies

Acute Gout Flare Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034. Potential key players in the emerging drug pipeline includes, Olatec Therapeutics, Dyve Biosciences, and others. 

Note: Detailed market segment assessment will be provided in the final report.

Acute Gout Flare Drugs Uptake

This section focuses on the sales uptake of potential Acute Gout Flare drugs that have recently been launched or are anticipated to be launched in the Acute Gout Flare market between 2020 and 2034. It estimates the market penetration of Acute Gout Flare drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Acute Gout Flare market.

The emerging Acute Gout Flare therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Acute Gout Flare market.

Note: Detailed assessment of drug uptake will be provided in the full report on Acute Gout Flare.

Acute Gout Flare Market Access and Reimbursement

DelveInsight’s ‘Acute Gout Flare– Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of Acute Gout Flare.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments. 

KOL Views

To keep up with current Acute Gout Flare market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the Acute Gout Flare domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Acute Gout Flare market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Acute Gout Flare unmet needs.

Acute Gout Flare: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the Johns Hopkins Arthritis Cente; Icahn School of Medicine at Mount Sinai, New York City; University of Florida Health, Jacksonville, FL; Rhumatologie, Lariboisière Hospital, and Université Paris Diderot Sorbonne Cité, Paris, France; Rheumatology Department, Sanno Medical Center, Tokyo, Japan; among others.

“An acute gout attack typically peaks within 12 to 24 hours of onset, followed by a gradual resolution even in the absence of treatment. Natural recovery from a gout attack usually spans about 7 to 14 days.”

Note: Detailed assessment of KOL Views will be provided in the full report on Acute Gout Flare.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the Acute Gout Flare Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Acute Gout Flare Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Acute Gout Flare. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Acute Gout Flare therapies.

Acute Gout Flare Report Insights

• Acute Gout Flare Patient Population
• Therapeutic Approaches
• Acute Gout Flare Pipeline Analysis
• Acute Gout Flare Market Size and Trends
• Acute Gout Flare Market Opportunities
• Impact of Upcoming Therapies

Acute Gout Flare Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Acute Gout Flare Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Acute Gout Flare Market
• Acute Gout Flare Drugs Uptake

Acute Gout Flare Report Assessment

• Acute Gout Flare Current Treatment Practices
• Unmet Needs
• Acute Gout Flare Pipeline Product Profiles
• Acute Gout Flare Market Attractiveness

Key Questions

• How common is Acute Gout Flare?
• What are the key findings of Acute Gout Flare epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
• What are the currently available treatments for Acute Gout Flare?
• What is the disease risk, burden, and unmet needs of Acute Gout Flare?
• At what CAGR is the Acute Gout Flare market and its epidemiology expected to grow in the 7MM during the forecast period (2024–2034)?
• How would the unmet needs impact the Acute Gout Flare market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of Acute Gout Flare in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2024–2034)?
• How many companies are currently developing therapies for the treatment of Acute Gout Flare?